NHLBI TOPMed: Pharmacogenomics of Hydroxyurea in Sickle Cell Disease (PharmHU)
Biomarkers (2)
- HbF_level_baseline - Level of fetal hemogloblin at baseline (phv00420473.v1.p1)
- HbF_level_final - Final level of fetal hemogloblin (phv00420474.v1.p1)
Demographics (2)
- age - Subject age at initiation of hydroxyurea (phv00420470.v1.p1)
- gender - Gender of participant (phv00420471.v1.p1)
Race and Ethnicity (1)
- race - Race of participant (phv00420472.v1.p1)
Other (17)
- ANALYTE_TYPE - Analyte Type (phv00420479.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00420478.v1.p1)
- Change_HbF_level - Change in level of fetal hemoglobin (phv00420475.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00420465.v1.p1)
- Funding_Source - Project funding source (phv00420482.v1.p1)
- HU_dose - Dose of hydroxyurea (phv00420476.v1.p1)
- IS_TUMOR - Tumor status (phv00420480.v1.p1)
- SAMPLE_ID - Sample ID (phv00420477.v1.p1)
- SAMPLE_ID - Sample ID (phv00420466.v1.p1)
- SEQUENCING_CENTER - Name of the center which conducted sequencing (phv00420481.v1.p1)
- study - Medical institution (phv00420469.v1.p1)
- Study_Name - TOPMed-assigned short study name (1:1 with TOPMed phs number) (phv00420485.v1.p1)
- SUBJECT_ID - De-identified Subject ID (phv00420468.v1.p1)
- SUBJECT_ID - Subject ID (phv00420464.v1.p1)
- SUBJECT_ID - Subject ID (phv00420467.v1.p1)
- TOPMed_Phase - TOPMed Phase (phv00420483.v1.p1)
- TOPMed_Project - TOPMed Project that funded sequencing (phv00420484.v1.p1)